Le Lézard
Classified in: Health, Science and technology, Business, Covid-19 virus
Subjects: FNC, VEN

CirrusMD Announces $20 Million in Series C Funding


DENVER, March 31, 2021 /PRNewswire/ -- CirrusMD, the fastest-growing provider of on-demand virtual care services, today announced that it has raised $20 million in a Series C round of funding led by Blue Venture Fund, with participation from 7wireVentures, Drive Capital and the Colorado Impact Fund, bringing total funding to $46 million. This round of funding will carry the company through its next phase of growth, as it continues to expand solution capabilities, enhance user and provider experiences, increase scalability, and drive innovation to support employer and health plan customers.

Series C Funding
"The last year has highlighted the importance of enabling fast, efficient communication between patients and providers, and CirrusMD has proven its ability to provide a solution that connects eligible members with a licensed doctor 24/7," said Kelsey Maguire, Managing Director of the Blue Venture Fund. "Health plans, like Blue Cross and Blue Shield companies, play an important role in shaping the next generation of patient care. We're excited to partner with CirrusMD as they modernize the consumer experience and advance care delivery."

"CirrusMD's text-first virtual care platform finally provides consumers with the ability to connect with a provider on their own terms ? receiving healthcare when and where they want it," said David Schonthal, Operating Partner at 7wireVentures. "We have been impressed with CirrusMD's unwavering commitment to improving the consumer experience, their superior ongoing engagement rates, and the extensive relationships they have built with leading health plans and employers across the country. We know that CirrusMD will play a critical role in the transformational story of virtual care."

Unique Experiences for Physicians, Patients and Customers
With the burgeoning demand for telemedicine, CirrusMD demonstrated unique scalability, keeping the average time to connect a patient with a board-certified physician to less than a minute. While other virtual care solutions replicate the traditional office visit and introduce familiar barriers, such as appointment scheduling and standing-by in a virtual waiting room, CirrusMD care is always available on-demand.

"Unlike any other telemedicine solution, CirrusMD's physician-directed, multi-specialty care model has proven scalable and effective in meeting the needs of this rapidly changing environment," said Andrew Altorfer, CEO, CirrusMD. "Our goal is to meet the patient where they are, in the way they want to communicate. We've enhanced our technology and focused on exceptional user and physician experiences, while doubling the size of our physician network. Today we're providing collaborative virtual care for patients in all 50 states, across a wide range of conditions including behavioral health, an area of increasing need during COVID-19."

A Care Model for the Modern World
The CirrusMD integrated care model guides patients on a journey that covers a full range of medical issues, whether primary or urgent care, chronic condition management, women's health, pediatrics and behavioral health. If needed, CirrusMD physicians can direct patients seamlessly to other in-network resources offered by the employer or health plan, helping increase utilization of invested benefits.

The CirrusMD platform and Provider Network currently:

"Based on the millions of encounters that we have managed, we have built an entirely unique data set due to our text-first workflow. Nearly every encounter is fully transcribed," added Altorfer. "This provides us with a very interesting data opportunity to move telemedicine from being a reactive solution into one that is proactive. We can create cohorts that will allow us to better engage patients across disease states and help them manage their medical needs through analytics and proactive interactions."

Building on Success
The Series C round of funding will continue the momentum the company experienced during 2020, the company's most significant year of growth. Notable statistics include:

About CirrusMD
CirrusMD is a different kind of telemedicine company. In less than a minute, patients reach a live, licensed physician via text-based (or web) app, then conduct a care encounter at their pace and convenience. Available 24/7/365, CirrusMD's integrated care is delivered via multi-specialty, board-certified doctors who can treat a broad range of conditions, from acute to chronic, and from primary care to specialty areas, including behavioral health. CirrusMD is available to nearly 10 million users across all 50 states, and exclusively offered through employers and health plans.

Learn how CirrusMD is transforming virtual care: cirrusmd.com

About the Blue Venture Fund
The Blue Venture Fund is a unique collaboration between BCBS companies, BCBSA, and Sandbox to which thirty-five BCBS companies have committed over $890 million across four funds. The Blue Venture Fund invests in promising emerging companies of strategic relevance to Blue Cross and/or Blue Shield companies and provides the portfolio with access to BCBS companies to deploy innovation at scale.  Sandbox is an independent company that provides healthcare-related investment management exclusively for the Blue Venture Fund. For more information, visit www.blueventurefund.com.

About 7wireVentures
7wireVentures is a preeminent venture capital firm that invests in early-stage digital health companies supporting an Informed Connected Health Consumer ? the epicenter of a consumer-first, tech-enabled convergence of the health and wellness markets. Fund successes, such as founding Livongo, are due in large part because the team are both seasoned operators and investors with extensive industry experience. Being highly selective with investments, the fund works side-by-side with founders to build companies that change the status quo and empower consumers to be better stewards of their health. As company builders, the 7wire team has assumed highly involved roles, in some cases, even pursuing a Hatch strategy to start promising new ventures.

SOURCE CirrusMD


These press releases may also interest you

at 01:05
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today the U.S. Food and Drug Administration (FDA) has approved the Vabysmo® (faricimab-svoa) 6.0 mg single-dose prefilled syringe (PFS) for use in the treatment of wet, or...

4 jui 2024
The global breast tissue expander market size is estimated to grow by USD 282.4 million from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  6.78%  during the forecast period. Increasing prevalence of breast cancer is...

4 jui 2024
The global sleep apnea implants market size is estimated to grow by USD 401.75 thousand from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 15.2% during the forecast period. Increasing prevalence of sleep apnea and...

4 jui 2024
The global implantable medical devices market size is estimated to grow by USD 53.5 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 8.08% during the forecast period. Rise in number of people with chronic...

4 jui 2024
The global transplant box market size is estimated to grow by USD 2.39 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  10.87%  during the forecast period. Increasing prevalence of chronic disorders is...

4 jui 2024
DelveInsight's BK Virus Infection Market Insights report includes a comprehensive understanding of current treatment practices, BK virus infection emerging drugs, market share...



News published on and distributed by: